Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia

Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, discusses the impact of pre-transplant molecular measurable residual disease (MMRD) and European Leukemianet (ELN) genetic classification in clinical outcomes for acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (alloHCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Muhammad Husnain

1:57
The role of CAR-T therapy in primary and secondary CNS lymphoma
Muhammad Husnain • 24 Apr 2022
5:38
PTCy in MMUD HCT: the University of Miami experience
Muhammad Husnain • 17 Feb 2021

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals